凝血酶介导的FVIII模拟抗体自调控实现止血反应动态控制
研究通过在emicizumab双臂铰链区插入凝血酶可切割肽,构建自调控(AR)FVIII模拟抗体。该抗体在生理条件下保留与亲本分子相当的FVIII模拟活性和纠正HA小鼠失血的能力,但在超生理凝血酶水平下可被蛋白水解灭活,从而减少aPCC联用诱导的促凝效应及微血管肺血栓形成。
要点
- AR-emicizumab保留与亲本相当的FVIII模拟活性(EC50可比)和纠正HA小鼠失血的能力。
- 超生理凝血酶水平下AR可被蛋白水解灭活,亲本emicizumab不受影响。
- AR可减轻aPCC联用诱导的促凝效应及微血管肺血栓形成,不改变抗体全身水平。
核心结论
- 凝血酶介导的自调控机制使FVIII模拟抗体的活性与局部止血需求对齐,可能改善HA治疗安全性。
研究设计与样本
- 在emicizumab双铰链区插入短凝血酶可切割肽,构建AR-FVIII模拟抗体并进行体外与HA小鼠体内评价。
主要发现
- AR-emicizumab的FVIII模拟活性EC50及纠正HA小鼠失血的效果与亲本emicizumab相当。
- 超生理凝血酶水平下AR-emicizumab被蛋白水解灭活,亲本emicizumab不受影响。
- AR-emicizumab减少aPCC联用诱导的促凝效应,并减轻亲本分子诱导的血小板消耗性凝血病和微血管肺血栓形成。
- AR-emicizumab未影响治疗抗体的全身水平。
关键数值与推荐
- AR-emicizumab的FVIII模拟活性EC50与亲本emicizumab可比(原文未报告具体数值)。
- 凝血酶生成试验中AR-emicizumab显著减弱emicizumab观察到的过度凝血酶峰值(原文未报告具体数值)。
临床怎么用
- AR策略可能为HA患者提供按需自限的止血治疗,降低联用aPCC时的血栓风险。
局限性
- 研究主要基于体外实验和HA小鼠模型,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Emicizumab has transformed hemophilia A (HA) management by enabling effective subcutaneous prophylaxis independent of inhibitor status. However, its constitutive activity and lack of sensitivity to anticoagulant feedback contribute to excessive thrombin generation under certain conditions, particularly when combined with bypassing agents, a liability increasingly recognized as a class effect of FVIII-mimetic antibodies. We engineered an "AutoRegulated" (AR) FVIII-mimetic antibody by integrating a short thrombin cleavable peptide sensitive to the proteolytic activity of thrombin in the hinge region of both emicizumab arms. Insertion of the peptide did not impair structural integrity and biological function with AR-emicizumab demonstrating EC50 values of FVIII-mimetic activity and correction of blood loss in HA mice comparable to the parental emicizumab. However, the presence of thrombin-mediated AR enabled thrombin-responsive proteolytic inactivation upon exposure to supra-physiological thrombin levels, whereas the parental emicizumab remained unaffected. The dynamic control provided by AR efficiently reduced the procoagulant effects induced by co-administration of activated Prothrombin Complex Concentrates (aPCC). In thrombin generation assays, AR-emicizumab significantly attenuated the excessive thrombin peak observed with emicizumab. Similarly, in vivo, the presence of thrombin-mediated AR prevented platelet consumptive coagulopathy and reduced the microvascular pulmonary thrombosis induced by the parental molecule without affecting the systemic levels of the therapeutic antibody. This on-demand self-limiting mechanism aligns therapeutic activity with local hemostatic needs, may offer a promising therapeutic approach for HA patients, while establishing a generalizable strategy to improve the safety profile of next-generation hemostatic biologics.
引用
- Muczynski V, Smith A, Baccaro A, et al. Thrombin-mediated AutoRegulation of FVIII-mimetic antibodies enabling dynamic control of the hemostatic response. Blood. 2026. PMID: 42913487. doi:10.1182/blood.2026034428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。